Kornimate/medical-research-clean huggingface dataset:
evaluating a novel onco-genetic brca testing counselling model among patients with ovarian cancer

Conditions: Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer

Summary: the overall objective of this study is to assess turnaround time, pre-brca test onco-genetic counselling quality and satisfaction with a new onco-genetic brca testing model.

this will be a prospective observational study of patients diagnosed with epithelial ovarian/fallopian tube/primary peritoneal cancer prior to, or at enrolment in this study. the study is descriptive in nature and does not attempt to test any specific a priori hypotheses. clinical teams (physicians and nurses) will be trained to discuss brca testing with ovarian cancer patients who meet study criteria and consent to participate in the study. patients will be recruited from participating sites in north america and europe. patients selected per the study inclusion and exclusion criteria will be consented for participation in the study. patients will be recruited during an estimated 12 month period and participating patients will be followed from enrollment in the study until provision of brca test results, final genetics counselling, and completion of satisfaction survey or death. a case report form will be developed to collect information on the primary variable of interest (i.e., turnaround time), patient and disease characteristics, medical history, treatment patterns and outcome of the brca test. in addition, a survey will be developed to evaluate patient's assessment of pre- brca onco-genetic counseling quality and satisfaction with onco-genetic testing process. finally, surveys will be developed to evaluate oncologist (or oncology nurse) and genetic counselor's assessment of the processes associated with the onco-genetic testing pathway.

Eligibility criteria:
inclusion criteria: * patients diagnosed with epithelial ovarian/fallopian tube/primary peritoneal cancer * patients aged 18 years or older at ovarian cancer diagnosis * provision of written informed consent * patient is able to read, write, and understand the material presented to them as part of this study, per the discretion of the physician exclusion criteria: * patients with low grade epithelial ovarian cancer or non-epithelial ovarian cancer * patients enrolled in an interventional clinical trial for ovarian cancer or other malignancy at the time of conduct of this study * patients with brca testing any time prior to the study enrollment
transcutaneous vagus nerve stimulation as a pain modulator in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: a single-blinded, randomized clinical trial, 68 patients divided into 2 groups: active and sham treatment. afferents of the auricular branch of vagus nerve are stimulated using a transcutaneous vagus nerve stimulation device (tens 7000tm). the electrode was placed in the left cymba concha with direct contact on the skin. the stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. the amplitude of the output current was between 0.25-2.0 ma as tolerated and 250 µs width at 25 hz. all participants initially will be evaluated before and after intervention and 3 months after the end of the sessions.

the included study population is 68. * group (1): (tvns group): this group of study subjects will include 34 patients of knee osteoarthritis and will be subjected to tvns. * group (2): (sham group): this group of study subjects will include 34 patients of knee osteoarthritis and will be subjected to sham treatment. description of the technique active treatment: afferents of the auricular branch of vagus nerve were stimulated using a t-vns device (tens 7000tm made by roscoe medical inc., will be used. tens 7000tm device was labeled as nerve stimulator and low-risk medical device (instruction manual for tens 7000). the electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. the stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. the amplitude of the output current was between 0.25-2.0 ma as tolerated and 250 µs width at 10 hz. sham procedure: for sham-t-vns device was turned 180°, stimulating the outer earlobe which does not contain fibers of the abvn. a similar protocol as for active stimulation was used. all participants initially will be evaluated before and after intervention and 3 months after the end of the sessions by the following: outcome measures and assessment questionnaires 1. visual analogue scale (vas) 2. paindetect questionnaire 3. dn4 questionnaire 4. radiological imaging 5. knee injury and osteoarthritis outcome score 6. hospital anxiety depression scale 7. physical function tests 8. quantitative sensory testing 9. the central sensitization inventory

Eligibility criteria:
inclusion criteria: * both genders. * adult over 18 years. * people who were diagnosed. * reported pain on visual analogue scale (vas)\>4/10. * able to understand the informed consent. exclusion criteria: * peptic ulcer * pace maker * asthma or severe chronic obstructive pulmonary disease * pregnancy. * cellulites, skin ulceration at area of therapy application. * inability to fulfill follow-up criteria.

Keywords: vagus nerve stimulation, knee osteoarthritis
a study of pegasys (pegylated-interferon alfa-2a) with or without ribavirin in patients with chronic hepatitis c who have participated in previous roche or roche partner protocols

Conditions: Hepatitis C, Chronic

Summary: this single arm study will provide treatment or re-treatment with pegasys as monotherapy or in combination with ribavirin (copegus), to patients with chronic hepatitis c (chc) who have participated in a previous roche or roche partner protocol where access to treatment or re-treatment was promised or deemed appropriate following completion of the original protocol ('donor' protocol). patients who qualify for treatment or re-treatment will begin pegasys monotherapy, at a maximum dose of 180 µg weekly, or combination therapy with copegus, 800-1200 mg daily, as continuation of treatment after the wash-out period defined in their donor protocol. pegasys treatment is not to exceed the approved treatment duration of 48 weeks in genotype g1 with a treatment-free follow up period of 24 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, ≥ 18 years of age. * chronic hepatitis c (chc) patients with compensated liver disease (child-pugh a) who have participated in a donor protocol where access to treatment or re-treatment with pegasys monotherapy or in combination with copegus was promised or deemed appropriate after completion of the donor protocol. exclusion criteria: * evidence of decompensated liver disease (child b or c cirrhosis).
body weight assessment in swiss primary school children: trend analysis over 10 years

Conditions: Overweight; Obesity

Summary: background: recent evidence from several countries has emerged suggesting that the increase in the prevalence of childhood obesity has slowed down substantially, or even leveled off. also in switzerland this trend has been observed. in 2002, 20.3% and 19.1% of boys and girls, respectively, were overweight or obese in switzerland. in 2007, the prevalence of overweight was significantly lower, with 11.3% and 9.9% of school-aged boys and girls, respectively, being overweight or obese. further trend analyses are necessary to confirm that the stabilizing trend observed reflects a long-term change in the rates of childhood overweight and obesity. objective and methods: the aim of the present study is to repeat the 2002 and 2007 national studies, in order to monitor the trend in the prevalence of overweight and obesity in 6-12 year old children in switzerland during this 5 respectively 10 year time period. height and weight will be measured and used to calculate body mass index (bmi). bmi references form the centers for disease control and prevention will be used to determine the prevalence of underweight (\< 5th percentile), overweight (≥ 85th and \< 95th percentile) and obesity (≥ 95th percentile). waist and hip circumference will be measured. moreover, skinfold thicknesses and bioelectrical impedance analysis will be performed to calculate body fat percentage.


Eligibility criteria:
inclusion criteria: * age 6-12 years * child is attending one of the selected classrooms exclusion criteria: * age below 6 or above 12 years

Keywords: childhood obesity prevalence
cefotaxime resistance in treatment of spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis

Summary: spontaneous bacterial peritonitis (sbp) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. cefotaxime has been the most extensively studied antibiotic for this infection. it is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. treatment of sbp by intravenous cefotaxime should be administered for a minimum 5 days. antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating sbp.


Eligibility criteria:
inclusion criteria: * patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic fluid infection exclusion criteria: * patients were excluded if they received antibiotics ten days prior to the hospital admission or there is evidence of secondary bacterial peritonitis, tuberculous peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal diseases

Keywords: profiles changes microorganisms cefotaxime sbp egyptian effective antibiotics
ed90 of norepinephrine and phenylephrine boluses under intensive treatment in preeclamptic patients

Conditions: Adverse Effect

Summary: the objective of this study is to investigate the ed90 of norepinephrine and phenylephrine boluses for treating postspinal anesthesia hypotension under intensive treatment in preeclamptic patients during cesarean section

post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. the incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. the 2016 asa guidelines for obstetric anesthesia suggest avoiding hypotension following spinal anesthesia in women and emphasize the use of vasopressors, specifically alpha-receptor agonists, as the preferred strategy to prevent and manage post-spinal anesthesia hypotension. the 2018 international consensus in the united kingdom and northern ireland recommends maintaining maternal systolic blood pressure above 90% of the baseline value following lumbar anesthesia, while avoiding dropping below 80% of the baseline value. currently, the threshold for maintaining blood pressure above 80% of the baseline value is widely adopted as a standard; however, limited evidence supports the advantage of sustaining maternal blood pressure above 90% of the baseline value. the objective of this study is to investigate the ed90 of norepinephrine and phenylephrine boluses for treating postspinal anesthesia hypotension under intensive treatment in preeclamptic patients during cesarean section

Eligibility criteria:
inclusion criteria: * 18-45 years * primipara or multipara * singleton pregnancy ≥32 weeks * american society of anesthesiologists physical status classification i to iii * scheduled for cesarean section under spinal anesthesia exclusion criteria: * baseline blood pressure ≥160 mmhg * body height \< 150 cm * body weight \> 100 kg or body mass index (bmi) ≥ 40 kg/m2 * eclampsia or chronic hypertension * hemoglobin \< 7g/dl * fetal distress, or known fetal developmental anomaly
special use-results surveillance on long term use of sogroya® in children with short stature due to growth hormone deficiency where epiphysial discs are not closed

Conditions: Growth Hormone Deficiency in Children

Summary: the purpose of the study is to investigate the safety and effectiveness of sogroya® in children with short stature due to growth hormone deficiency where epiphysial discs are not closed under real-world clinical practice in japan. the study will last for about 1 year (at shortest) to 3 years (at longest) depending on when the participant takes part in the study. the participant will be asked to answer questionnaire(s) about how they feel about the growth hormone (gh) product treatment once during the study (at about 3 months after starting the sogroya® treatment) and about 3 months after starting the sogroya® treatment.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. the decision to initiate treatment with commercially available sogroya® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study. both gh treatment naïve and non-naïve children are eligible. 3. male or female age 0 to 18 years (exclusive) at the time of signing informed consent. 4. diagnosis with short stature due to ghd where epiphysial discs are not closed according to local normal clinical practice. exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study. 2. treatment with any investigational drug within 30 days prior to baseline (the starting date of sogroya® treatment). 3. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. 4. contraindication described in approved product labelling in japan. 1. patients with hypersensitivity to the active substance or to any of the excipients 2. patients with malignant tumour 3. female patients who are either pregnant or likely to be pregnant
metabonomics to investigate effects of healthy diets on blood pressure: the omniheart study

Conditions: Hypertension

Summary: to compare the urinary metabolomes on individuals undergone three different healthy diets--a carbohydrate-rich diet, a protein-rich diet, or a diet rich in unsaturated fat.

background: this study based on the omniheart dietary intervention study, a randomized, three period cross-over feeding study that compared the effects on blood pressure and plasma lipids of three dash-like diets: a carbohydrate-rich (carb) diet pattern, a rich in protein (prot) and a rich in unsaturated (mufa) fat, predominantly monounsaturated fat diet (see full details of omniheart dietary intervention https://clinicaltrials.gov/ct2/show/record/nct00051350). this metabonomic study aims to evaluate the feasibility of identifying individuals showing variation in clinical response to three different healthy diets, with the purpose of reducing cardiovascular disease (cvd) risk, using proton nuclear magnetic resonance (nmr) based metabolic phenotyping approach.

Eligibility criteria:
inclusion criteria: * with pre-hypertension (systolic bp of 120 to 139 mmhg and/or diastolic bp of 80 to 89 mmhg) or stage 1 hypertension (systolic bp of 140 to 159 mm hg and/or diastolic bp of 90 to 99 mm hg) and without diabetes or prior cvd exclusion criteria: * cvd or diabetes

Keywords: hypertension
the use of international gerdq questionnaire

Conditions: Gastroesophageal Reflux Disease

Summary: there are three main directions for use gerdq in practice. first of all, gerdq can be used to diagnose gerd with an accuracy comparable to the accuracy of diagnosis of gerd by the specialist (gastroenterologist). using gerdq can evaluate the impact of disease on the patient's life and help in choosing treatment of gerd, as well as direct assessment of treatment efficacy. in connection with mentioned above, this study is devoted to the estimation of possibility to use gerdq in routine practice of russian physicians.

observational non-interventional study on the use of international gerdq questionnaire for the diagnosis of gastroesophageal reflux disease in the russian practice

Eligibility criteria:
inclusion criteria: * signing of informed consent to participate in the study * patients of both sexes, 18 years and older * planned esophagogastroduodenoscopy exclusion criteria: * surgical intervention for upper digestive tract (surgery for gastroesophageal reflux disease, peptic ulcer disease, etc.) in the past * the presence of contraindications for esophagogastroduodenoscopy or ph-metry * refusal to sign informed consent * acceptance of antisecretory drugs (proton pump inhibitors, h2-receptor blockers), antacids and prokinetics for 7 days before enrollment * pregnancy * confirmed or suspected malignancy * impairment of the mental sphere * acceptance of nsaids (including acetylsalicylic acid at a dose of 150 mg / day), cytostatics, antibiotics (tetracyclines, lincosamides) at enrollment and during the preceding 30 days

Keywords: gerd gerd q questionnaire
study of bone disease in older hiv-infected adults

Conditions: Osteopenia; Osteoporosis; HIV Infection; Aging; HIV Infections

Summary: this study will look to see if there are changes in the blood cells that are associated with bone disease and sort out effects that are due to the hiv virus itself, the medications and see if faster aging occurs in the cells of hiv infected persons. bone disease will be measured by a special x-ray called a dexa scan. a dexa scan is used by doctors to see if someone has normal bone mass for their age or if there is thinning of the bones. the purposes of this study are: * to learn how common bone disease is in hiv infected patients over the age of 50 years that receive their care at the core center * to see what are the common causes of bone disease in older hiv infected persons * to see if there are differences in blood cells and levels of cytokines in patients who do or do not have bone disease, as this may help researchers determine the cause of bone disease.


Eligibility criteria:
inclusion criteria: * hiv-1 infection documented by elisa and confirmed by western blot * treatment with antiretroviral drugs for at least 12 months * age 50-70 years * cd4 count \> 350 cells/mm3 for at least 6 months * hiv-rna undetectable (\< 75 copies/ml for at least 6 months) exclusion criteria: * known bone disease (primary or metastatic malignancy, osteomalacia) * treatment for bone disease (bisphosphonates, calcitonin, strontium, sodium fluoride, synthetic pth, or high-dose vitamin d \[\> 800 iu daily\]).

Keywords: treatment experienced
prolactin change in chinese patients with schizophrenia after antipsychotics treatment

Conditions: Schizophrenia; Antipyretics Toxicity; Prolactin Excess

Summary: objective: hyperprolactinemia(hprl) which can result in a series of prolactin-related symptoms is a frequent adverse effect of antipsychotics. the investigators are interested to explicate the characteristics of serum prolactin level change after taking different antipsychotics and related factors. method: 1. review of electronic medical records of schizophrenia patients who were brought to shanghai mental health center since january 1, 2007. 2. the investigators collect their information, and then 1. set serum prolactin level after first 1-month antipsychotic treatment as primary outcome. secondary outcomes are prolactin levels tested at other time points. 2. variables will range from antipsychotic kinds, dosage, treatment duration and blood concentration to demographic information, to disease history, to clinical treatment on hyperprolactinemia, to laboratory test results, such as blood routine examination, biochemistry, sex hormone levels and so on. 3. after data cleaning and management, we will apply logistic regression, cox regression, receiver operating characteristic curve (roc) and machine learning to * analyze factors of prolactin level; * establish a model of prolactin change with time; * propose optimal monitoring time of prolactin according to prolactin change with time; * analyze correlation among antipsychotics, prolactin and clinical characters, for the purpose to supply objective evidence for antipsychotic treatment.


Eligibility criteria:
inclusion criteria: * diagnosed as schizophrenia according to diagnostic and statistical manual of mental disorders(dsm)-5; * were taking or going to take antipsychotics; * have the results of serum prolactin level. exclusion criteria: * other mental disorder; * suffered endocrinic diseases of pituitary or thyroid gland; * suffered other organic brain diseases; * have the history of tobacco or alcohol abuse, or psychoactive drug substance abuse.
assessment of the impact of soft tissue mobilization on the scar in patients after cesarean section

Conditions: Cesarean Section Complications

Summary: the aim of the study is to assess the impact of soft tissue mobilization on the scar in patients after cesarean section. an additional aim is to assess the relationship between the initial stiffness and elasticity of the scar and the age of the patients, the number of cesarean sections performed, as well as the time that has passed since the last cesarean section. two physiotherapeutic interventions will be performed in the form of mobilization of the soft tissues (myofascial release techniques) of the lower abdominal area and the cesarean section scar, two weeks apart. the researchers will perform an assessment before and after each therapeutic session, as well as 2 weeks after the last therapy (follow-up). the level of satisfaction with life (satisfaction with life scale (swls)) as well as the area of the cesarean section scar (vancouver scar scale (vss), scar assessment according to the mustoe classification) will be analyzed. researchers will also assess the sequence of abdominal muscle contractions during activation of the pelvic floor muscles (ultrasound examination) and quantify the state of soft tissue tension using the myotonpro measuring device.


Eligibility criteria:
inclusion criteria: * women aged 18-45, * undergone at least 1 cesarean section in a period of not less than 6 months, * not using physiotherapy for a cesarean section scar exclusion criteria: * women under 18 and over 45, * pregnant women, * presence of abdominal mesh, * condition after abdominoplasty; nephrectomy; hysterectomy; cystectomy, * uterine fibroids, * stoma, * occurrence of neurological symptoms (exclusion based on a functional test including the following elements: trunk flexion test in a sitting position (slump test), babinski test and clonic reflex test, tension tests for the sciatic nerve (passive straight leg raise test) and bowstring test and femoral nerve test (in lying on the front and on the side), examination of knee and ankle reflexes, as well as assessment of superficial sensation and strength of indicator muscles in the innervation of the lumbar-sacral spine), * positive result of pain provocation tests: axial compression of the spine and maximum compression of the intervertebral foramen in the lumbosacral spine area, * presence of contraindications to myofascial release therapy (active cancer, deep vein thrombosis, aneurysms, infectious diseases, viral and bacterial infections, acute inflammation and fever), * women who underwent cc surgery in less than 6 months, * previous surgical treatment and spine injury, * vertical scar after cesarean section, * use of physiotherapy treatments in the last six months, * additionally the following comorbid conditions: cancer, diabetes, osteoporosis, diseases of the digestive system, circulatory system, rheumatic, mental and gynecological diseases, pregnancy

Keywords: soft tissue mobilization scar cesarean section